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Objective. To describe obstetrical and neonatal outcomes in Canadian women with rheumatoid arthritis (RA) or systemic lupus
erythematosus (SLE). Methods. An administrative database of hospitalizations for neonatal delivery (1998–2009) from Calgary,
Alberta was searched to identify women with RA (38 pregnancies) or SLE (95 pregnancies), and women from the general
populationmatchedonmaternalageandyearofdelivery(150and375pregnancies,resp.).Conditionallogisticregressionwasused
to calculate odds ratios (OR) for maternal and neonatal outcomes, adjusting for parity. Results. Women with SLE had increased
odds for preeclampsia or eclampsia (SLE OR 2.16 (95% CI 1.10–4.21; P = 0.024); RA OR 2.33 (95% CI 0.76–7.14; P = 0.138)).
Women with SLE had increased odds for cesarean section after adjustment for dysfunctional labour, instrumentation and previous
cesarean section (OR 3.47 (95% CI 1.67–7.22; P<0.001)). Neonates born to women with SLE had increased odds of prematurity
(SLE OR 6.17 (95% CI 3.28–11.58; P<0.001); RA OR 2.66 (95% CI 0.90–7.84; P = 0.076)) and of SGA (SLE OR 2.54 (95% CI
1.42–4.55; P = 0.002); RA OR 2.18 (95% CI 0.84–5.66; P = 0.108)) after adjusting for maternal hypertension. There was no excess
risk of congenital defects in neonates. Conclusions. There is increased obstetrical and neonatal morbidity in Canadian women with
RA or SLE.
1.Introduction
Historically, epidemiology studies have documented delete-
rious eﬀects of rheumatic disease on pregnancy [1]. Over
the last ﬁfteen years, the approach to treating rheumatic
diseases has changed substantially, with a focus on aggressive
treatment to achieve remission, and an increased selection
of immunosuppressive therapies. Preconception and prena-
tal care have received increased attention as these newer
therapies have become available, requiring additional patient
counseling on potential teratogenicity [2]. It is worthwhile
to examine what impact these changes may have had on
obstetricaland neonataloutcomesin womenwithrheumatic
disease.
In fact, recent evidence from large administrative data-
bases from the United States, Taiwan, Norway, Denmark,
and Sweden is in keeping with the historical literature,
with demonstrated discrepancies in obstetrical and neonatal
outcomes for rheumatology patients relative to the general
population. At the population level, women with rheuma-
toid arthritis (RA) or systemic lupus erythematosus (SLE)
experience more preeclampsia [3–8] and have a higher risk
ofcesareansection[3–7].Theirneonatesareatincreasedrisk
of being small for gestational age (SGA) and premature [3–
7, 9]. There may be increased perinatal mortality [7, 9].
We are unaware of any contemporary data on obstetrical
or neonatal outcomes in Canadian patients with rheumatic
disease; therefore, we used population-based data from a
Canadian urban centre to determine obstetrical outcomes in
women with RA or SLE over the last decade, relative to those
in women of the general population. Maternal outcomes of
interestincludedthefrequencyofpreeclampsiaoreclampsia,
cesarean section, the occurrence of postpartum infections,
andtheeﬀectofthesecomplicationsonthelengthofstayand
the need for intensive care unit admission. We also examined
neonatal outcomes, including the frequency of prematurity2 International Journal of Rheumatology
and congenital defects, gestational size, and the need for spe-
cial care unit admission. An estimation of the risks attendant
to childbearing will allow rheumatologists and obstetrical
care providers to improve the prenatal information that is
provided to patients with rheumatic disease.
2. Methods
2.1. Data Source. The study population was determined
fromapopulation-basedhospitaldischargeabstractdatabase
fortheCalgaryZoneofAlbertaHealthServices(withapopu-
lation of 1.3 million people and three tertiary care hospitals),
forﬁscalyears1998/1999 to 2008/2009, afterethical approval
fromtheUniversityofCalgaryHealthResearchEthicsBoard.
Prior to 2002, coding was performed using the International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁca-
tion (ICD-9-CM) for diagnosis and procedures. Thereafter
the International Classiﬁcation of Diseases, Tenth Revision,
Canadian Enhancement (ICD-10-CA), and the Canadian
Classiﬁcation of Health Interventions (CCI) for diagnoses
and procedures were used, respectively. Standard admission
and discharge information for all hospital separations using
16 (ICD-9-CM) and 25 (ICD-10-CA) diagnostic and 10
procedure code ﬁelds are captured. This same data is used
by the Canadian Institute for Health Information in their
surveillance activities, and coders receive signiﬁcant training
and are audited to ensure accuracy. The database exists
primarily for administrative purposes within the context
of provincial health care delivery and therefore does not
include information on an individual’s rheumatic disease
characteristics such as duration, severity, or treatment.
2.2. Study Population. Women between the ages of 12 and 55
years who had a hospital separation for delivery of a neonate
(gestational age >20 weeks) and with diagnostic codes for
RA (ICD-9-CM 714.0; ICD-10-CA M05 or M06) or SLE
(ICD-9-CM 710.0; ICD-10-CA M32) were identiﬁed from
the database. The general population comparison group
consisted of women with an obstetrical admission randomly
selected from the same administrative database, in a 4:1
ratio, matched on maternal age (within two years) and
year of delivery (same calendar year). Some women with
rheumatic disease had more than one delivery during the
study period, and each delivery was matched to a new con-
trol. The neonates were identiﬁed by their unique personal
health numbers recorded in a ﬁeld of the mother’s chart.
Onlysingletonbirthswereincludedintheanalysis.Advanced
maternal age was considered to be ≥36 years of age.
2.3. Outcomes. Diagnostic and procedure codes were used
to identify outcomes and covariates. The maternal outcomes
of interest for this study were (1) maternal preeclampsia or
eclampsia (including worsening of preexisting hypertension
during pregnancy) (ICD-9-CM 642.x; ICD-10-CA O10-
O16), (2) cesarean section (ICD-9-CM procedures 74.x;
ICD-10-CA procedures 5MD60), and (3) postpartum infec-
tion (ICD-9-CM 670.0, 658.4, or 674.3; ICD-10-CA O85
and O86). Neonatal outcomes of interest were (1) congen-
ital defects (ICD-9-CM 740–759; ICD-10-CA Q00-Q99),
(2) prematurity, and (3) gestational size. The Public Health
Agency of Canada deﬁnes preterm births as those occurring
before 37 weeks of gestation and SGA as babies who were less
than the 10th percentile for weight based on their gestational
age, weight, and sex [10]. We also determined the length of
stay and intensive care requirements for both mothers and
neonates. We included information on readmissions within
a one-year time period for both the mother and the neonate
to identify delayed events.
2.4.ExplanatoryVariables. Parity (ﬁrstbirth, ≥secondbirth)
wasincludedinallmodels.Additionalcovariatesforcesarean
section were dysfunctional labour, instrumentation to assist
delivery,andpreviouscesareansection.Additionalcovariates
for postpartum infection were instrumentation and cesarean
section. Neonatal outcomes were also adjusted for maternal
hypertension (preexisting cases and new diagnoses).
2.5. Statistical Methods. Conditional logistic regression was
usedtocalculatecrudeoddsratios(OR)andtheir95%conﬁ-
denceintervals(CI)fortheoutcomesofinterest.Anadjusted
OR was calculated, taking into account speciﬁc confounders
for each outcome that were available as described above.
Due to the sample size retrieved from our search, we limited
the number of explanatory variables in our analysis. The
predetermined alpha level for statistical signiﬁcance was set
at 5% (two tailed). Statistical analysis was performed using
STATA IC 10.0 (StataCorp, College Station, Texas) and R
version 2.13.0 (available at http://www.r-project.org/).
3. Results
We matched 38 singleton births in women with RA and 95
singleton births in women with SLE to 150 and 375 singleton
births in women of the general population, respectively.
The mean age of women with RA was 32 years (standard
deviation (SD) 5.5, range 21–42) and with SLE was 30 years
(SD5.5,range20–45).Twenty-ninepercent(29%)ofwomen
with RA and 13% of women with SLE were of advanced
maternal age. The median parity for women with RA or SLE
was 0, compared to a median parity of 1 for women of the
general population.
Maternal outcomes are summarized in Table 1.W o m e n
with RA or SLE had a longer mean length of stay in
hospital (mean diﬀerence RA: 0.8 days; mean diﬀerence SLE:
1.8 days). Preeclampsia or eclampsia occurred in 18.4% of
pregnancies of women with RA and 16.8% of pregnancies
of women with SLE, compared to 7.3% and 9.3% of
their controls, respectively. A large proportion of women
with RA or SLE delivered by cesarean section (RA: 34.2%
versus 21.3%; SLE: 43.2% versus 23.7%). Women with SLE
experienced a higher frequency of postpartum infections.
These infections were either of the uterine cavity (n = 2),
the surgical wound (n = 2), or were coded as puerperal
sepsis with no location speciﬁed (n = 2). In two SLE
patients, maternal infection was associated with stillbirth
of an extremely premature baby. All other infections were
associated with either cesarean section or instrumentation
for delivery.International Journal of Rheumatology 3
Table 1: Summary of maternal outcomes.
Outcome Women with RA
n = 38
RA controls
n = 150
Women with SLE
n = 95
SLE controls
n = 375
Length of stay (days), mean (SD) 3.0 (1.5) 2.2 (1.2) 4.2 (5.3) 2.3 (2.4)
Preeclampsia, n (%)
Mild 7 (18.4) 11 (7.3) 9 (9.5) 33 (8.8)
Severe/eclampsia 0 (0.0) 0 (0.0) 7 (7.4) 2 (0.5)
Cesarean section, n (%) 13 (34.2) 32 (21.3) 41 (43.2) 89 (23.7)
Postpartum infection, n (%) 0 (0.0) 1 (0.7) 6 (6.3) 5 (1.3)
1 year readmission, n (%) 7 (15.8) 6 (4.7) 13 (13.7) 22 (5.9)
n: number; SD: standard deviation.
Table 2: Summary of neonatal outcomes.
Outcome
Neonates of women
with RA
n = 38
Neonates of RA controls
n = 150
Neonates of women with
SLE
n = 95
Neonates of SLE
controls
n = 375
Prematurity, n (%)
<28 weeks gestation 0 (0.0) 0 (0.0) 3 (3.2) 0 (0.0)
28–34 weeks gestation 1 (2.6) 1 (0.7) 8 (8.4) 7 (1.9)
34–37 weeks gestation 7 (18.4) 12 (8.0) 22 (23.2) 19 (5.1)
Requiring intensive care, n (%) 11 (28.9) 17 (11.3) 34 (35.8) 50 (13.3)
Small for gestational age, n (%) 11 (28.9) 18 (12.0) 24 (25.3) 41 (10.9)
Congenital defects∗, n (%) 0 (0.0) 3 (2.0) 2 (2.1) 6 (1.6)
1 year readmission, n (%) 2 (5.3) 8 (5.3) 10 (10.5) 18 (4.8)
n: number; SD: standard deviation.
∗Includes chromosomal abnormalities, cleft lip and/or palate, and talipes calcaneovalgus.
In the ﬁrst postpartum year, more women with RA
or SLE were readmitted compared to their controls. Two
of these readmissions were speciﬁcally for SLE ﬂares. The
median time to readmission was similar between women
with rheumatic disease (80 days, interquartile range (IQR)
6–288) and their controls (94 days, IQR 9–225). No women
required intensive care during either the index admission or
during a readmission.
Neonatal outcomes are summarized in Table 2. Although
the mean number of gestational weeks was similar between
babies born to mothers with RA or SLE and their controls
(RA: mean 38.1 (SD 2.0) versus 36.2 (SD 10.0) weeks; SLE:
mean 37.2 (SD 3.4) versus 37.5 (SD 7.6) weeks), a higher
proportion of the neonates of mothers with rheumatic dis-
ease were born prematurely. These neonates more frequently
required intensive care support. Intubation was required in
5.3% of neonates born to mothers with RA compared to
4.7%fortheircontrolsand4.2%ofneonatesborntomothers
with SLE compared to 1.9% for their controls. There were
three stillbirths in the SLE group compared to two in the
controlgroup,butspeciﬁcdetailsforthecausesofdeathwere
not available.
Babies born to mothers with rheumatic disease were
smaller, with 28.9% of RA babies (versus 12.0%) and 25.3%
of SLE babies (versus 10.9%) meeting the criteria for SGA.
The diﬀerence in birth weight between babies born to
mothers with rheumatic disease and their controls was
more pronounced in SLE. The mean birth weight diﬀerence
between RA neonates and their controls was 298 grams for
females (95% CI 10–586; P = 0.0425) and 388 grams for
males(95%CI102–675;P =0.0084),comparedto533grams
(95% CI 344–722; P < 0.001) for female SLE neonates and
512 (95% CI 310–713; P < 0.001) for male SLE neonates.
Neonates of women with rheumatic disease were not at
increased risk of readmission. There was also no evidence
of excess congenital defects in babies born to women with
rheumatic disease.
Controlling for parity, interesting trends emerged for
obstetrical and neonatal outcomes in RA or SLE. Women
with rheumatic disease remain at substantial risk for
preeclampsia or eclampsia compared to the general pop-
ulation (SLE OR 2.16 (95% CI 1.10–4.21; P = 0.024);
RA OR 2.33 (95% CI 0.76–7.14; P = 0.138)) (Table 3).
Women with SLE were also more likely to deliver by cesarean
section (adjusted OR 3.47 (95% CI 1.67–7.22; P < 0.001))
compared to their controls, after additionally adjusting for
dysfunctional labor, instrumentation, and previous cesarean
section. The possible increased risk of postpartum infections
in women with SLE was negated once adjustments for
instrumentationatdeliveryandcesareansectionsweremade.
Neonates of women with rheumatic disease were more likely
to be preterm compared to general population controls
after additionally adjusting for maternal hypertension (SLE
adjusted OR 6.17 (95% CI 3.28–11.58; P < 0.001); RA4 International Journal of Rheumatology
Table 3: Local and worldwide published odds ratios (and 95% conﬁdence intervals) for obstetrical and neonatal complications.
Publication and
country Disease
Pregnancy-
related
hypertension∗
Cesarean section Prematurity (<37
weeks gestation)† Size‡ Postpartum
infection
Barnabe, Canada RA 2.33 (0.76–7.14) 1.89 (0.53–6.78)§ 2.66 (0.90–7.84)|| 2.18 (0.84–5.66)|| NR
SLE 2.16 (1.10–4.21) 3.47 (1.67–7.22)§ 6.17 (3.28–11.58)|| 2.54 (1.42–4.55)|| 2.07 (0.50–8.54)¶
Chakravarty,
United States [3]
RA 1.4 (1.0–2.0) 1.5 (1.2–1.9) NR 2.3 (1.2–4.3) NR
SLE 3.4 (2.9–4.1) 1.6 (1.4–1.9) NR 3.7 (2.7–5.2) NR
Clowse, United
States [4]∗∗ SLE 3.0 (2.7–3.3) 1.7 (1.6–1.9) 2.4 (2.1–2.6) 2.6 (2.2–3.1)
Sepsis: 3.5
(2.0–6.0)
Pneumonia: 4.3
(3.1–5.9)
Reed, United
States [5]†† RA 1.55 (0.97–2.50) 1.66 (1.22–2.26) 1.78 (1.21–2.60) 1.51 (0.94–2.43) NR
Lin, Taiwan [6] RA 2.23 (1.60–3.12) 1.20 (1.09–1.33) 1.18 (0.98–1.40) 1.20 (1.05–1.37) NR
Wallenius,
Norway [7]
Chronic
inﬂammatory
arthritides
0.60 (0.22–1.62) 1.71 (1.13–2.59) 1.91 (1.13–3.24) 1.59 (0.99–2.54) NR
Nørgaard,
Denmark and
Sweden [9]
RA 1.50 (1.13–1.94) 1.78 (1.56–2.02) 1.53 (1.23–1.90) 1.60 (1.25–2.03) NR
Wolfberg, United
States [8]‡‡
RA 1.8 (0.2–13.4) NR NR NR NR
SLE 5.7 (2.0–16.2) NR NR NR NR
All values are crude odds ratios (95% conﬁdence intervals) unless otherwise stated.
RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; OR odds ratio; CI: conﬁdence interval; SGA: small for gestational age; IUGR: intrauterine
growth restriction; NR: not reported.
∗All pregnancy-related hypertensive disorders. In the studies by Clowse, Reed, Lin, Wallenius, Nørgaard, and Wolfberg odds ratios for preeclampsia are
reported.
†Clowse reports preterm labor. Nørgaard reports prematurity as 32–36 weeks gestation.
‡All report small for gestational age, except Chakravarty and Clowse which report intrauterine growth restriction.
§Adjusted for dysfunctional labor (including uterine inertia, malpresentation, or obstruction) and previous cesarean section.
||Adjusted for instrumentation and caesarean section.
¶Adjusted for maternal hypertension.
∗∗Adjusted for comorbidities, pregnancy complications, and medical computations.
††Relative risk calculated from odds ratio; adjusted for age, smoking, year. ‡‡Adjusted for age.
adjusted OR 2.66 (95% CI 0.90–7.84; P = 0.076)). These
neonates were also more likely to meet SGA criteria (SLE
adjustedOR2.54(95%CI1.42–4.55;P =0.002);RAadjusted
OR 2.18 (95% CI 0.84–5.66; P = 0.108)).
4. Discussion
Our results demonstrate that women with RA or SLE, in
a Canadian urban setting with universal health coverage,
have adverse obstetrical outcomes. They have at least twice
the odds of developing preeclampsia or eclampsia relative
to the general population, and a large proportion deliver
by cesarean section. Neonates of women with RA or SLE
are at least three times as likely to be premature and small
for gestational age. These neonates require admission to
the intensive care unit for additional supportive care and
therefore may be at increased risk for long-term morbidity.
Table 3 summarizes the results of our study compared to
those reported in other countries.
A few prospective cohorts have examined pregnancy
outcomes in SLE and inﬂammatory arthritis. A prospective
Canadian SLE cohort found that women with active renal
disease,comparedtothosewithoutactiverenaldisease,more
frequently had pregnancy-induced hypertension and disease
ﬂare, with lower birth weight babies and more congenital
malformations[11].Twoprospectivecohortsofwomenwith
inﬂammatory polyarthritis and RA found that higher disease
activity during pregnancy resulted in babies of lower birth
weight [12, 13].
The biologic mechanisms responsible for diﬀerential
pregnancy outcomes have not been determined [14]. Preg-
nancy in normal individuals is associated with a shift from
a Th1 cytokine milieu to a Th2 predominant one. Women
with RA have been shown to have the same response,
which may account for remission of disease observed during
pregnancy. However, endocrine eﬀects and other potential
immunomodulatory mechanisms have not been adequately
studied. Inﬂammation likely plays a role, as increased diseaseInternational Journal of Rheumatology 5
activity during pregnancy has resulted in babies of lower
birth weight, as demonstrated in the prospective RA cohorts
[12, 13].
Our study is limited by the inability to adjust for
important disease-related confounders for the women with
RA or SLE, such as disease duration, disease activity, or
medication exposures in the pregestational or gestational
period. We also are unable to comment on an individual’s
characteristicswhichmayaﬀectpregnancyoutcomes,suchas
smoking status, body mass index, ethnicity, or the quality or
quantity of prenatal care received for each individual. These
variables are not available in the discharge abstract database.
Our analysis considered each individual birth occurring in
a woman with RA or SLE, with new controls selected each
time,inordertooptimizethesizeofourdataset,theresulting
eﬀect estimates, and their precision. We adjusted for parity
(ﬁrst birth or ≥second birth) rather than restricting the
analysis to ﬁrst birth only such as was done in the studies by
Wallenius et al. [7] and Nørgaard et al. [9] due to the limited
number of births to women with RA or SLE in our dataset.
Our use of conditional logistic regression did not allow
us to account for outcomes in mothers with more than one
birth during the study period. In the SLE group fourteen
mothers had two births, and three mothers in the RA group
had two births. The associations among outcomes for these
mothers may have resulted in conﬁdence intervals that were
narrower than warranted by the data. To test for the impact
ofobstetricaloutcomesforthosewithmorethanonebirthin
the study period, we attempted to ﬁt a mixed-eﬀects model
with random eﬀects for pair and mother. However, these
models did not converge, possibly due to the small number
ofmotherswithmorethanonebirthduringthestudyperiod
and also because those with more than one birth during
the study period were only in the RA or SLE group. As
a sensitivity analysis, we also ﬁtted GEE logistic regression
models that conditioned on the matching variables and
used a working correlation matrix to account for mothers
with more than one birth. The inclusion of the working
correlation matrix had negligible impact on the conﬁdence
intervals and P values (data available upon request).
Our ﬁndings are not at particular risk for selection bias,
as the universal Canadian health care system ensures equal
access to hospital care, and all admissions are captured. A
potential source of bias may have been related to errors in
coding, with the potential for misclassiﬁcation of either the
outcome or the disease status determination [15]. Patients
with mild rheumatic disease that did not complicate the
pregnancy or hospital course could have been missed in the
coding process. The eﬀect of this error could falsely increase
the event rate in the control group, as women with RA or
SLE would erroneously be included here. Determination of
outcome events would depend on the accuracy of the chart
and data extraction by the coder. Coders are trained and
audited regularly, so the potential source of this error is small
and would aﬀect both case and control groups equally, thus
maintaining the eﬀect size between the two groups.
We propose the following explanations to explain why
there is ongoing discrepancy in obstetrical outcomes for
rheumatic disease patients in the modern treatment era. It
is possible that improved treatment approaches have had
little or no impact on the underlying biologic mechanisms
responsible for adverse obstetrical outcomes, in particular
for women who have had long-standing disease. Women
planning a pregnancy may be unwilling to be exposed
to newer agents or aggressive management for fear of
teratogenic eﬀects. Women with more severe disease, who
m a yh a v ep r e v i o u s l yb e e nu n a b l et oc o n c e i v e ,m a yn o w
achieve pregnancy due to aggressive immunosuppressive
treatment and may be at higher risk for obstetrical and
neonatal complications. Reproductive technologies are also
increasingly available, aﬀecting the risk of complications as
well. It is also possible that treatment is preventing even
more deleterious outcomes from occurring that cannot be
measured, as that would be counterfactual.
In summary, our study conﬁrms that women with RA
or SLE remain at increased odds of developing preeclampsia
or eclampsia, undergoing a cesarean section, and a trend to
developing more postpartum infections. Their neonates are
morefrequentlybornpreterm,areoflowerweight,andmore
frequently require intensive care. These risks can be com-
municated to patients with rheumatic disease and highlight
the need for collaborative care between rheumatologists and
prenatal care providers.
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